The US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.
Janssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.
Lecture on “The Crisis of Psychopharmacology” at the scientific colloquium of the Department of Psychiatry and Psychotherapy of the University of Rostock.
On June 28 and 29, 2018, the Summer School “Psychopharmacology”, organized by the German Society for Psychiatry and Psychotherapy, Psychosomatics and Neuroscience (DGPPN), will be held in Berlin.
My presentation on “long-term treatment with psychotropic drugs” (“Langzeittherapie mit Psychopharmaka”) on the web platform “Frag-den-Professor”.
Andrea Cipriani from the University of Oxford and colleagues have recently published the largest and most comprehensive meta-analysis of the efficacy of antidepressants in the Lancet. The paper is worth dealing with more intensively.
A video of my lecture on “Polypharmacy and Pharmacokinetics”, which I gave at the “Psychiatrie-Akademie” in Brugg, Switzerland on January 11th, 2018. This talk was given in German.
Work with me at the Central Institute of Mental Health (CIMH) in Mannheim and build with me the future of psychiatry.
The Westdeutscher Rundfunk (WDR) on October 8th and 9th, 2017, broadcasted an interesting feature on the “new paths of psychiatry”, which contains many statements I made during an interview on the future of psychopharmacology.
The interesting new antipsychotic compound cariprazine was recently approved by the European Medicines Agency (EMA). Its launch in Germany will be a new touchstone for the German Act on the Reform of the Market for Medicinal Products (AMNOG).